Freenome is a biotech company revolutionizing early cancer detection with advanced blood tests and AI technology.

Freenome is a biotech company revolutionizing early cancer detection with advanced blood tests and AI technology.

Allelica’s PREDICT module is a resource for clinical laboratories and healthcare providers to generate personalized PRS reports for common diseases. The end-to-end solution starts with patient genotype data generated from microarray or lcWGS technology. Users can then choose from a range of diseases to report on, including coronary artery disease, breast cancer, and Alzheimer’s disease. In just a few hours, the platform applies Allelica’s predictive analytics to calculate individual genetic risk scores for the diseases of interest. The technology accounts for a patient’s ancestry by comparing the risk scores to a distribution matched to the individual’s ancestry. The resulting report communicates the individual’s genetic risk of disease in a concise and comprehensible document.

Allelica has created a secure and trusted platform for Polygenic Risk Score analysis and reporting to equip health systems and clinical laboratories with cutting-edge tools to reduce the impact of common disease through genomic medicine. 

All processes performed on the Allelica platform are fully HIPAA and GDPR-compliant. ISO 13485 and ISO 9001 certifications guarantee that Allelica applies medical device quality management processes every step of the way.

Allelica is working with leading health systems and genetics laboratories in the United States and across Europe to advance disease prevention through widened application of PRS in healthcare.